Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2015 Jul 7;7(3):1233–1243. doi: 10.3390/cancers7030834

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2015 by the authors; licensee MDPI, Basel, Switzerland.

This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

Methylation of CLDN11 in nevus cell nevi (N), primary malignant melanoma (P) and melanoma metastases (M). (a) Methylation of CLDN11 was analyzed by COBRA. PCR products (157 bp) from bisulfite-treated DNA were digested with TaqI (+) or mock digested (−) and resolved on 2% gel. DNA from HeLa and fibroblast (HF) was utilized as methylated and unmethylated control. Sizes of a 100 bp ladder (M) are marked; (b) Methylation analysis of CLDN11 by bisulfite pyrosequencing. 11 CpGs within PCR products generated from nevus cell nevi (N), primary MM (P/primaries) and MM metastases (M) and in vitro methylated DNA (IVM) were analyzed in technical replicates. M48 is a lymph node metastasis and all other metastases originated from skin; (c) Comparison between methylation of MM (primaries, metastases) and NCN. Bar charts indicate percentage of cases with unmethylated (unm. <10%), weakly methylated (10% to 20%) and strongly methylated (>20%) CLDN11. Significance was calculated with the two-tailed Fisher exact probability test.